Venture Houston 2018
Skip Content

15 October 2015

23andme decodes $115m series E

The genetic testing company has now raised $225m after Alphabet, Illumina and WuXi PharmaTech took part in a Fidelity-led round that valued it at $1.1bn.

Author: Robert Lavine, News Editor

US-based personal genetics analysis service 23andme raised $115m yesterday in a series E round backed by Google Ventures, internet and technology company Alphabet’s corporate venturing arm.